Literature DB >> 23090881

Height, age at menarche and risk of hormone receptor-positive and -negative breast cancer: a cohort study.

Rebecca Ritte1, Annekatrin Lukanova, Anne Tjønneland, Anja Olsen, Kim Overvad, Sylvie Mesrine, Guy Fagherazzi, Laure Dossus, Birgit Teucher, Karen Steindorf, Heiner Boeing, Krasimira Aleksandrova, Antonia Trichopoulou, Pagona Lagiou, Dimitrios Trichopoulos, Domenico Palli, Sara Grioni, Amalia Mattiello, Rosario Tumino, Carlotta Sacerdote, José Ramón Quirós, Genevieve Buckland, Esther Molina-Montes, María-Dolores Chirlaque, Eva Ardanaz, Pilar Amiano, Bas Bueno-de-Mesquita, Franzel van Duijnhoven, Carla H van Gils, Petra Hm Peeters, Nick Wareham, Kay-Tee Khaw, Timothy J Key, Ruth C Travis, Sanda Krum-Hansen, Inger Torhild Gram, Eiliv Lund, Malin Sund, Anne Andersson, Isabelle Romieu, Sabina Rinaldi, Valerie McCormack, Elio Riboli, Rudolf Kaaks.   

Abstract

Associations of breast cancer overall with indicators of exposures during puberty are reasonably well characterized; however, uncertainty remains regarding the associations of height, leg length, sitting height and menarcheal age with hormone receptor-defined malignancies. Within the European Prospective Investigation into Cancer and Nutrition cohort, Cox proportional hazards models were used to describe the relationships of adult height, leg length and sitting height and age at menarche with risk of estrogen and progesterone receptor negative (ER-PR-) (n = 990) and ER+PR+ (n = 3,524) breast tumors. Height as a single risk factor was compared to a model combining leg length and sitting height. The possible interactions of height, leg length and sitting height with menarche were also analyzed. Risk of both ER-PR- and ER+PR+ malignancies was positively associated with standing height, leg length and sitting height and inversely associated with increasing age at menarche. For ER+PR+ disease, sitting height (hazard ratios: 1.14[95% confidence interval: 1.08-1.20]) had a stronger risk association than leg length (1.05[1.00-1.11]). In comparison, for ER-PR- disease, no distinct differences were observed between leg length and sitting height. Women who were tall and had an early menarche (≤13 years) showed an almost twofold increase in risk of ER+PR+ tumors but no such increase in risk was observed for ER-PR- disease. Indicators of exposures during rapid growth periods were associated with risks of both HR-defined breast cancers. Exposures during childhood promoting faster development may establish risk associations for both HR-positive and -negative malignancies. The stronger associations of the components of height with ER+PR+ tumors among older women suggest possible hormonal links that could be specific for postmenopausal women.
Copyright © 2012 UICC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23090881     DOI: 10.1002/ijc.27913

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  29 in total

1.  Menopausal hormone therapy and breast cancer risk: effect modification by body mass through life.

Authors:  Marie Søfteland Sandvei; Lars J Vatten; Elisabeth Krefting Bjelland; Anne Eskild; Solveig Hofvind; Giske Ursin; Signe Opdahl
Journal:  Eur J Epidemiol       Date:  2018-08-06       Impact factor: 8.082

2.  Pubertal growth and adult height in relation to breast cancer risk in African American women.

Authors:  Kimberly A Bertrand; Hanna Gerlovin; Traci N Bethea; Julie R Palmer
Journal:  Int J Cancer       Date:  2017-09-13       Impact factor: 7.396

3.  Sex-specific regulation of weight and puberty by the Lin28/let-7 axis.

Authors:  Christina Corre; Gen Shinoda; Hao Zhu; Diana L Cousminer; Christine Crossman; Christian Bellissimo; Anna Goldenberg; George Q Daley; Mark R Palmert
Journal:  J Endocrinol       Date:  2015-12-23       Impact factor: 4.286

4.  Younger pubertal age is associated with allergy and other atopic conditions in girls.

Authors:  Chi-Chen Hong; Ashley Pajak; Susan L Teitelbaum; Nita Vangeepuram; Maida Galvez; Susan M Pinney; Gayle Windham; Lawrence H Kushi; Frank M Biro; Mary S Wolff
Journal:  Pediatr Allergy Immunol       Date:  2014-12-29       Impact factor: 6.377

5.  Height and Body Size in Childhood, Adolescence, and Young Adulthood and Breast Cancer Risk According to Molecular Subtype in the Nurses' Health Studies.

Authors:  Erica T Warner; Rong Hu; Laura C Collins; Andrew H Beck; Stuart Schnitt; Bernard Rosner; A Heather Eliassen; Karin B Michels; Walter C Willett; Rulla M Tamimi
Journal:  Cancer Prev Res (Phila)       Date:  2016-09

6.  Body size throughout adult life influences postmenopausal breast cancer risk among hispanic women: the breast cancer health disparities study.

Authors:  Esther M John; Meera Sangaramoorthy; Lisa M Hines; Mariana C Stern; Kathy B Baumgartner; Anna R Giuliano; Roger K Wolff; Martha L Slattery
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-10-28       Impact factor: 4.254

7.  Effect of Polygonatum odoratum extract on human breast cancer MDA-MB-231 cell proliferation and apoptosis.

Authors:  Yu Tai; Yi-Ming Sun; Xue Zou; Qiong Pan; Ya-Dong Lan; Qiang Huo; Jing-Wen Zhu; Fei Guo; Chang-Quan Zheng; Cheng-Zhu Wu; Hao Liu
Journal:  Exp Ther Med       Date:  2016-08-30       Impact factor: 2.447

8.  Sex hormones and the risk of keratinocyte cancers among women in the United States: A population-based case-control study.

Authors:  Lawrence F Kuklinski; Michael S Zens; Ann E Perry; Anala Gossai; Heather H Nelson; Margaret R Karagas
Journal:  Int J Cancer       Date:  2016-04-15       Impact factor: 7.396

Review 9.  Exposures to synthetic estrogens at different times during the life, and their effect on breast cancer risk.

Authors:  Leena Hilakivi-Clarke; Sonia de Assis; Anni Warri
Journal:  J Mammary Gland Biol Neoplasia       Date:  2013-02-08       Impact factor: 2.673

Review 10.  Breast cancer risk accumulation starts early: prevention must also.

Authors:  Graham A Colditz; Kari Bohlke; Catherine S Berkey
Journal:  Breast Cancer Res Treat       Date:  2014-05-13       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.